
Please try another search
Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-cells. It also engages in the development of CYAD-01, a CAR T-cell product candidate based on the natural killer group 2D (NKG2D); CYAD-02, an autologous NKG2D-based CAR T-cell candidate used to target the NKG2D ligands (NKG2DL) MICA/B to prevent cell fratricide and improve cell persistence; and CYAD-211, an allogeneic B-cell maturation antigen (BCMA)-targeting CAR T-cell candidate. In addition, the company offers C-Cathez, an intra-myocardial injection catheter. It has a license agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; research and development collaboration, and license agreements with Hr for the use of shRNA to downregulate such targets in immune cells and the combination of shRNAs with a chimeric antigen receptor in immune cells; and a license agreement with Mesoblast to develop and commercialize C-Cathez. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Name | Age | Since | Title |
---|---|---|---|
Michel E. J. Lussier | 69 | 2007 | Co-Founder & Non-Executive Director |
Marco L. Davila | - | 2016 | Member of Scientific Advisory Board |
Margo R. Roberts | 70 | 2018 | Member of Scientific Advisory Board |
Marina Udier Blagovic | - | 2020 | Independent Director |
Hilde Windels | 60 | 2017 | Independent Chairwoman of the Board |
Serge Goblet | 67 | 2008 | Non-Executive Director |
Hinrich Abken | - | 2016 | Member of Scientific Advisory Board |
Jean-Christophe Marine | - | - | Member of Scientific Advisory Board |
Christopher LiPuma | - | 2022 | Non-Executive Director |
Gerry Graham | - | - | Member of Scientific Advisory Board |
Dominic G. Piscitelli | 50 | 2020 | Independent Director |
Ami Patel Shah | - | 2021 | Non-Executive Director |
Ann Ager | - | - | Member of Scientific Advisory Board |
Jonathan James | - | 2024 | Non-Executive Director |
John Campbell | - | - | Member of Scientific Advisory Board |
Andrea Gothing | - | 2024 | Non-Executive Director |
Matthew R. Kane | 49 | 2024 | CEO & Executive Director |
Sage Mandel | - | 2024 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review